The next round of national harvest into the variety schedule out.

Medicine Network Monthly News shows that the biological products, Chinese medicine collection of blood products, vaccines, growth hormone and other not too involved in The Formula of Chinese Medicine particles, Chinese medicine tablets and chinese traditional medicine exclusive varieties are not consideredThe latest news from biopharmaceuticals and traditional Chinese medicine collection came yesterday according to industry media news for the national health insurance bureau held on the second day of the biological products (including insulin) and Traditional Chinese medicine symposium experts at an investor conference to share the basic situation of the meetingThe basic points are as follows: This medical insurance bureau symposium is only to organize the relevant experts to conduct a preliminary discussion to express relevant viewsThe experts at this meeting have some controversy about the future biological products and the problems related to the collection of traditional Chinese medicine, especially how to divide the quality level on the basis of the evaluation of non-quality consistencyFrom the time process to see this symposium is only the first expert to explore exchanges if the policy smoothly advanced as soon as possible also to come out at the beginning of the first draft to further explore researchThe future of the country may still do some exploration of the re-combination of the province's specific work arrangements to the entire belt procurement down to implement, from the participant category, the early stage may choose to participate in the pilot of less-controversial varieties of quality, such as insulin and some biosimilarsFrom the category, blood products, vaccines, growth hormone and so on do not involve Chinese medicine formula particles and Chinese medicine tablets are not very involvedSince the beginning of the first round of belt procurement annual band purchase winning varieties expansion of the third batch of the third batch of belt volume procurement is also about to beginAt the same time, some provinces began to explore the purchase of drug band quantity without consistency evaluation This symposium has determined the trend of expanding the selection of collected varieties from chemical generics to biopharmaceuticals and traditional Chinese medicine coverageFocus on insulin does not consider the exclusive varieties of traditional Chinese medicine experts revealed that the symposium is still in the first stage is mainly to invite some industry experts to talk about biological products, Chinese medicine two categories of products in the exclusive varieties of drugs are not considered in the scopeIt is worth noting that this did not involve specific biological products and Chinese medicine species also did not specific rule-making is mainly some professional opinions and academic views of some of the experts of the dispute point is mainly in the absence of consistent evaluation on the basis of biological products and traditional Chinese medicine classification issues or the classification of qualityIn the case of insulin, for example, future collection involves the internal classification of insulin (second, third and its internal categories) and the classification of quality (e.gwhether there is a difference between domestic insulin and imported insulin) is more controversial)This is also where the collection controversy for traditional Chinese medicines, in addition to biological products, is that it is relatively difficult to measure quality because of the different raw materials in their processesThe category of species selection of biological products mainly includes insulin and some biosimilar drugs but does not include blood products and vaccines because the problems of blood products involving raw materials are not suitable for the purchase of the amount; Although the collection symposium did not identify any varieties but the total return is traceableExperts say that in the future, priority will be given to products that are not controversial - products with supply problems, quality problems or patent disputes will not be taken into account There has been a precedent in local collection and collection to some extent the procurement of biological products band quantity in our country At the beginning of the year, Wuhan took the lead in the country to start the procurement of insulin band quantity, and the monthly Qinghai Province's belt procurement list also includes human haemoglobin and other products Southwest Securities analysis of biological products in China's development time is relatively late than the chemical and traditional Chinese medicine part of the product quality level of higher level of research and development more difficult number of larger production enterprises relatively small market competition is relatively moderate; But it's important to note that the experts are clear about the value of health insurance purchases - that companies that pay for something worth buying rather than spending money to feed biosimilars are using policies to encourage companies to do more sophisticated imitations or innovations but don't pay for you Therefore, the future of the volume procurement of biological products will continue to focus on public hospital channels sales of products with large sales and health insurance catalog - recombinant protein drugs such as insulin is the focus area of collection will accelerate the introduction of biosimilars may also enter the collection The discovery of traditional Chinese medicine with volume procurement is not new month sourcing of Qinghai Province belt quantity procurement catalog, including blood plug pass, thrombosis pass, sputum heat clean and other Chinese medicine injections to some extent in the tide of medical insurance fees in the chinese medicine is not privileged In addition, in recent years, the State Drug Administration announced the drug adverse reaction monitoring feedback to see that although the proportion of Chinese medicine injections and Chinese medicine in the overall adverse reactions is basically stable, the basic proportion of Chinese medicine injections in the overall Chinese medicine in recent years there is a small increase in adverse reactions improvement is not obvious Southwest Securities analysis analysis that: in the hospital side sales of larger efficacy in the medical insurance catalog of oral Chinese medicine varieties into the collection of catalog is more likely to go into the collection of the catalog, the main retail channels, non-medical insurance, partial consumption of traditional Chinese medicine into the lower pre-sales impact of the larger Chinese medicine injections into the catalog is more likely to enter the catalog